Dopaminergic inhibitory effects were markedly reduced by domperidone, D2-like receptor antagonist, and to a lesser extent by SCH 23390, the D1-like receptor antagonist.

Notably, D2-like receptors have a 10- to 100-fold greater affinity for dopamine than D1-like receptors. 1 The processes of DA synthesis, reuptake, and metabolism occurring at a dopaminergic synapse.4 ...

Motokazu Uchigashima, Toshihisa Ohtsuka, Kazuto Kobayashi, Masahiko Watanabe, Dopamine synapse is a neuroligin-2–mediated contact between dopaminergic presynaptic and GABAergic postsynaptic structures ...

A review of both pharmacologic and non-pharmacologic therapies for the treatment of L-Dopa-induced dyskinesia in patients with Parkinson's disease.

Qiaoling Cui, Qian Li, Hongyan Geng, Lei Chen, Nancy Y. Ip, Ya Ke, Wing-Ho Yung, Dopamine receptors mediate strategy abandoning via modulation of a specific prelimbic cortex–nucleus accumbens pathway ...

Results for the use of dopaminergic agonists in AM have been varied, which may be due to the site of the lesion giving rise to the AM. In one study of four patients who had global akinesia ...

RELATED: Other methods are being explored to reduce or reverse dopaminergic neurodegeneration. South Korea biotech Peptron, for example, is repurposing a GLP-1 receptor agonist, a common class of ...

Alterations in dopaminergic innervation and receptors in focal cortical dysplasia. Brain, 2025; DOI: 10.1093/brain/awaf080 ...

A preclinical study sheds a light on the structure and function of GPR6, which is a key player in Parkinson's disease. The insights could guide future research and development of new therapeutics.

"D1- and D2-like Receptors Differentially Mediate the Effects of Dopaminergic Transmission on Cost–Benefit Evaluation and Motivation in Monkeys." PLos Biology (First published: July 01, 2021 ...